Is there a such thing as 'too little benefit' in oncology?
Sensible Medicine
SEPTEMBER 15, 2024
Recently John Mandrola, once again, stepped out of his lane. About a recent, cancer trial, which was celebrated by oncologists, he said this: In fact, John’s observation is broadly true for this revolutionary class of medications. Although these drugs— checkpoint inhibitors— are great for melanoma and cutaneous squamous cell cancer, they aren’t wonder drugs and many uses are marginal.
Let's personalize your content